BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 30429893)

  • 1. Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.
    Camorani S; Hill BS; Collina F; Gargiulo S; Napolitano M; Cantile M; Di Bonito M; Botti G; Fedele M; Zannetti A; Cerchia L
    Theranostics; 2018; 8(18):5178-5199. PubMed ID: 30429893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer.
    Camorani S; Hill BS; Fontanella R; Greco A; Gramanzini M; Auletta L; Gargiulo S; Albanese S; Lucarelli E; Cerchia L; Zannetti A
    Theranostics; 2017; 7(14):3595-3607. PubMed ID: 28912898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
    Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
    Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies.
    Camorani S; Caliendo A; Morrone E; Agnello L; Martini M; Cantile M; Cerrone M; Zannetti A; La Deda M; Fedele M; Ricciardi L; Cerchia L
    J Exp Clin Cancer Res; 2024 Mar; 43(1):92. PubMed ID: 38532439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
    Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
    Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition.
    Garcia E; Luna I; Persad KL; Agopsowicz K; Jay DA; West FG; Hitt MM; Persad S
    Sci Rep; 2021 Jun; 11(1):11757. PubMed ID: 34083676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
    Forte L; Turdo F; Ghirelli C; Aiello P; Casalini P; Iorio MV; D'Ippolito E; Gasparini P; Agresti R; Belmonte B; Sozzi G; Sfondrini L; Tagliabue E; Campiglio M; Bianchi F
    BMC Cancer; 2018 May; 18(1):586. PubMed ID: 29792166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of triple negative breast cancer cell migration and metastases formation is prevented by chloroquine in a pre-irradiated mouse model.
    Bouchard G; Therriault H; Geha S; Bérubé-Lauzière Y; Bujold R; Saucier C; Paquette B
    BMC Cancer; 2016 Jun; 16():361. PubMed ID: 27282478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
    Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
    Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.
    D'Ippolito E; Plantamura I; Bongiovanni L; Casalini P; Baroni S; Piovan C; Orlandi R; Gualeni AV; Gloghini A; Rossini A; Cresta S; Tessari A; De Braud F; Di Leva G; Tripodo C; Iorio MV
    Cancer Res; 2016 Sep; 76(18):5562-72. PubMed ID: 27402080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity.
    Ferrari-Amorotti G; Chiodoni C; Shen F; Cattelani S; Soliera AR; Manzotti G; Grisendi G; Dominici M; Rivasi F; Colombo MP; Fatatis A; Calabretta B
    Neoplasia; 2014 Dec; 16(12):1047-58. PubMed ID: 25499218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.
    Bartholomeusz C; Xie X; Pitner MK; Kondo K; Dadbin A; Lee J; Saso H; Smith PD; Dalby KN; Ueno NT
    Mol Cancer Ther; 2015 Dec; 14(12):2773-81. PubMed ID: 26384399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.
    Plantamura I; Casalini P; Dugnani E; Sasso M; D'Ippolito E; Tortoreto M; Cacciatore M; Guarnotta C; Ghirelli C; Barajon I; Bianchi F; Triulzi T; Agresti R; Balsari A; Campiglio M; Tripodo C; Iorio MV; Tagliabue E
    Mol Oncol; 2014 Jul; 8(5):968-81. PubMed ID: 24747080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.